Key facts
- It has raised $112.0M; the latest was Early Stage VC ($42.0M) in Nov 2025.
- Notable investors include ARCH Venture Partners, Atlas Venture, 5AM Ventures, Sanofi.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Lifordi Immunotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Lifordi Immunotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lifordi Immunotherapeutics
Developer of targeted antibody-drug conjugates (ADCs) designed to treat autoimmune and inflammatory disorders. The company offers a proprietary ADC platform demonstrating enhanced efficacy and safety in disease models, enabling innovative therapies that address unmet needs in immunology and inflammation.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Employees
- 23
- Website
- lifordi.com/
- Ownership
- Privately Held (backing)
Lifordi Immunotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lifordi Immunotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lifordi Immunotherapeutics in its N-PORT filings yet. We sweep new filings monthly.